These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 19198835)

  • 21. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
    Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
    J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ability of low-dose cyclophosphamide to overcome metastasis-induced immunosuppression.
    Tuttle TM; Fleming MD; Hogg PS; Inge TH; Bear HD
    Ann Surg Oncol; 1994 Jan; 1(1):53-8. PubMed ID: 7834429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bryostatin 1-activated T cells can traffic and mediate tumor regression.
    Tuttle TM; Bethke KP; Inge TH; McCrady CW; Pettit GR; Bear HD
    J Surg Res; 1992 Jun; 52(6):543-8. PubMed ID: 1528028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
    Winter H; Hu HM; McClain K; Urba WJ; Fox BA
    J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.
    Zeng R; Spolski R; Finkelstein SE; Oh S; Kovanen PE; Hinrichs CS; Pise-Masison CA; Radonovich MF; Brady JN; Restifo NP; Berzofsky JA; Leonard WJ
    J Exp Med; 2005 Jan; 201(1):139-48. PubMed ID: 15630141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bryostatin 1 activates T cells that have antitumor activity.
    Tuttle TM; Inge TH; Wirt CP; Frank JL; McCrady CM; Bear HD
    J Immunother (1991); 1992 Aug; 12(2):75-81. PubMed ID: 1504056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of CD8+ murine T cells from tumor-draining lymph nodes by phorbol dibutyrate plus calcium ionophore.
    Tuttle TM; Inge TH; McCrady CM; Bethke KP; Bear HD
    J Immunother (1991); 1992 Jul; 12(1):32-40. PubMed ID: 1386251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes.
    Baldwin NG; Rice CD; Tuttle TM; Bear HD; Hirsch JI; Merchant RE
    J Neurooncol; 1997 Mar; 32(1):19-28. PubMed ID: 9049859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trial.
    Bear HD; Roberts J; Cornell D; Tombes MB; Kyle B
    Cancer Immunol Immunother; 2001 Jul; 50(5):269-74. PubMed ID: 11499810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fate and function of anti-CD3/CD28-activated T cells following adoptive transfer: IL-2 promotes development of anti-tumor memory T cells in vivo.
    Hughes DP; Baskar D; Urban FF; Friedman MS; Braun TM; McDonagh KT
    Cytotherapy; 2005; 7(5):396-407. PubMed ID: 16236629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-metastatic activity induced by the in vivo activation of purified protein derivative (PPD)-recognizing Th1 type CD4+ T cells.
    Shinomiya Y; Harada M; Kurosawa S; Okamoto T; Terao H; Matsuzaki G; Shirakusa T; Nomoto K
    Immunobiology; 1995 Aug; 193(5):439-55. PubMed ID: 8522359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy.
    Mueller K; Schweier O; Pircher H
    Eur J Immunol; 2008 Oct; 38(10):2874-85. PubMed ID: 18825743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytotoxic T lymphocytes generated by short-term in vitro TCR stimulation in the presence of IL-4 are therapeutically effective against B16 melanoma.
    Chang ML; Chen YT; Su YC; Kung JT
    J Biomed Sci; 2003; 10(6 Pt 1):644-50. PubMed ID: 14576467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
    J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
    Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
    Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of in vitro sensitized cells generated by in vivo priming with OK-432 for adoptive immunotherapy of the poorly immunogenic B16-Bl6 melanoma.
    Mukai S; Kato H; Kimura S; Asai K; Kawahito Y; Inoue M; Yamamura Y; Sano H; Sugino S; Shu S; Kondo M
    Int J Immunopharmacol; 1996 Feb; 18(2):141-53. PubMed ID: 8799364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.